[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

MA51288A - Analogues d'incrétine et leurs utilisations - Google Patents

Analogues d'incrétine et leurs utilisations

Info

Publication number
MA51288A
MA51288A MA051288A MA51288A MA51288A MA 51288 A MA51288 A MA 51288A MA 051288 A MA051288 A MA 051288A MA 51288 A MA51288 A MA 51288A MA 51288 A MA51288 A MA 51288A
Authority
MA
Morocco
Prior art keywords
incretin
analogues
incretin analogues
Prior art date
Application number
MA051288A
Other languages
English (en)
Inventor
Jorge Alsina-Fernandez
Tamer Coskun
Lili Guo
Hongchang Qu
Original Assignee
Lilly Co Eli
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lilly Co Eli filed Critical Lilly Co Eli
Publication of MA51288A publication Critical patent/MA51288A/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/26—Glucagons
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/605—Glucagons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/542—Carboxylic acids, e.g. a fatty acid or an amino acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Endocrinology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Diabetes (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Toxicology (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Emergency Medicine (AREA)
  • Child & Adolescent Psychology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Measurement And Recording Of Electrical Phenomena And Electrical Characteristics Of The Living Body (AREA)
  • Details Of Garments (AREA)
MA051288A 2017-12-21 2018-12-14 Analogues d'incrétine et leurs utilisations MA51288A (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201762608613P 2017-12-21 2017-12-21

Publications (1)

Publication Number Publication Date
MA51288A true MA51288A (fr) 2021-03-31

Family

ID=65003519

Family Applications (1)

Application Number Title Priority Date Filing Date
MA051288A MA51288A (fr) 2017-12-21 2018-12-14 Analogues d'incrétine et leurs utilisations

Country Status (26)

Country Link
US (3) US11542313B2 (fr)
EP (1) EP3727426A1 (fr)
JP (3) JP6961838B2 (fr)
KR (2) KR102622642B1 (fr)
CN (1) CN111491658B (fr)
AR (1) AR113486A1 (fr)
AU (1) AU2018388962B2 (fr)
BR (1) BR112020010244A2 (fr)
CA (1) CA3084005C (fr)
CL (1) CL2020001635A1 (fr)
CO (1) CO2020006255A2 (fr)
CR (1) CR20200255A (fr)
DO (1) DOP2020000123A (fr)
EA (1) EA202091290A1 (fr)
EC (1) ECSP20032650A (fr)
IL (1) IL275468A (fr)
JO (1) JOP20200137A1 (fr)
MA (1) MA51288A (fr)
MX (2) MX2020006548A (fr)
MY (1) MY199143A (fr)
PE (1) PE20210162A1 (fr)
PH (1) PH12020551025A1 (fr)
SG (1) SG11202005606VA (fr)
TW (3) TW202415675A (fr)
UA (1) UA129012C2 (fr)
WO (1) WO2019125938A1 (fr)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW202415675A (zh) * 2017-12-21 2024-04-16 美商美國禮來大藥廠 腸促胰島素(incretin)類似物及其用途
KR102779458B1 (ko) * 2018-11-12 2025-03-12 톈진 인스티튜트 오브 파마슈티컬 리서치 씨오., 엘티디. 글루카곤 유도 펩티드 및 이의 용도
CA3148347A1 (fr) * 2019-08-19 2021-02-25 Michael E. Kopach Procedes de fabrication d'analogues d'incretine
TWI795698B (zh) * 2019-12-18 2023-03-11 美商美國禮來大藥廠 腸促胰島素(incretin)類似物及其用途
CA3173129A1 (fr) * 2020-03-25 2021-09-30 Antoine Charles Olivier HENNINOT Dosage d'une fois par jour de composes peptidiques de l'agoniste du recepteur du gip et leurs utilisations
EP4236991A1 (fr) 2020-10-30 2023-09-06 Novo Nordisk A/S Agonistes triples du récepteur de glp-1, gip et glucagon
CN114685642B (zh) * 2020-12-29 2024-03-29 浙江和泽医药科技股份有限公司 一种肠促胰岛素类似物药学上可接受盐及制备方法和用途
KR20240118914A (ko) 2021-01-20 2024-08-05 바이킹 테라퓨틱스 인코포레이티드 대사 및 간 질환 치료를 위한 조성물 및 방법
TW202423476A (zh) 2021-03-23 2024-06-16 美商美國禮來大藥廠 含腸促胰島素(incretin)類似物之組合物及其用途
AU2022280225A1 (en) * 2021-05-26 2024-01-04 The United Bio-Technology (Hengqin) Co., Ltd. Multi-agonist and use thereof
WO2022268029A1 (fr) * 2021-06-21 2022-12-29 广东东阳光药业有限公司 Agoniste triple pour récepteurs glp-1, gcg et gip
IL309604A (en) * 2021-06-23 2024-02-01 Lilly Co Eli An incretin analog for use in glycemic control and weight management
JP2024543441A (ja) * 2021-11-19 2024-11-21 メッドシャイン ディスカバリー インコーポレイテッド ステープルペプチド及びその使用
TWI828434B (zh) * 2021-11-19 2024-01-01 大陸商南京明德新藥研發有限公司 釘合肽及其應用
CN116162147B (zh) * 2021-11-24 2023-10-03 成都奥达生物科技有限公司 一种长效胰岛素类似物
CN114957387B (zh) * 2022-05-18 2023-06-20 华南理工大学 一种具有降血糖作用的巴旦木多肽及其制备方法与应用
PE20251068A1 (es) 2022-08-29 2025-04-09 Lilly Co Eli Composiciones para suministro oral
KR20250075689A (ko) * 2022-09-28 2025-05-28 선샤인 레이크 파르마 컴퍼니 리미티드 Glp-1/gcg/gip 삼중-수용체 작용제 및 이의 용도
CN120303283A (zh) 2022-10-05 2025-07-11 伊莱利利公司 用于肠降血糖素合成的肽
AU2023385357A1 (en) * 2022-11-21 2025-06-05 Eli Lilly And Company Process for preparing a gip/glp1 dual agonist
WO2024141760A1 (fr) 2022-12-30 2024-07-04 Algipharma As Compositions et procédés pour augmenter la biodisponibilité systémique d'un agent thérapeutique polypeptidique subissant une administration orale
US20240270821A1 (en) 2023-01-31 2024-08-15 Eli Lilly And Company Gip/glp1/gcg tri-receptor agonists and uses thereof
WO2024213022A1 (fr) * 2023-04-11 2024-10-17 上海多米瑞生物技术有限公司 Analogues d'incrétine et leur procédé de préparation, et utilisation
WO2024252366A1 (fr) * 2023-06-09 2024-12-12 Sun Pharmaceutical Industries Limited Agonistes du récepteur double glp-1/gip, double glp-1/gcg et triple glp-1/gip/gcg
KR20240176455A (ko) 2023-06-15 2024-12-24 노보 노르디스크 에이/에스 시클로덱스트린을 포함하는 약학적 제형
CN117024528B (zh) * 2023-07-07 2024-03-22 杭州信海医药科技有限公司 一种Retatrutide的制备方法
WO2025087353A1 (fr) * 2023-10-26 2025-05-01 齐鲁制药有限公司 Polypeptide présentant une activité multi-agoniste et son utilisation
CN119823233A (zh) * 2025-03-18 2025-04-15 杭州思诺达医药科技有限责任公司 瑞他鲁肽的合成方法及瑞他鲁肽

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP6108659B2 (ja) * 2008-06-17 2017-04-05 インディアナ ユニバーシティー リサーチ アンド テクノロジー コーポレーションＩｎｄｉａｎａ Ｕｎｉｖｅｒｓｉｔｙ Ｒｅｓｅａｒｃｈ Ａｎｄ Ｔｅｃｈｎｏｌｏｇｙ Ｃｏｒｐｏｒａｔｉｏｎ 代謝疾患および肥満の治療のためのｇｉｐに基づいた混合アゴニスト
UA98911C2 (uk) 2009-03-27 2012-06-25 Ґлаксо Ґруп Лімітед Лікувальні злиття та кон'югати інсулінотропних пептидів з доменним антитілом, що зв'язує сироватковий альбумін
BR112012018104A2 (pt) * 2010-01-20 2017-10-17 Zeland Pharma As tratamento de doenças cardíacas
AR080592A1 (es) * 2010-03-26 2012-04-18 Lilly Co Eli Peptido con actividad para el gip-r y glp-1-r, formulacion famaceutica que lo comprende, su uso para preparar un medicamento util para el tratamiento de diabetes mellitus y para inducir la perdida de peso
EP2707713A2 (fr) * 2011-05-10 2014-03-19 Zealand Pharma A/S Composés sélectifs pour une signalisation d'agonistes doubles de glu-glp1
WO2014049610A2 (fr) 2012-09-26 2014-04-03 Cadila Healthcare Limited Peptides en tant que triples agonistes des récepteurs de gip, glp-1 et glucagon
TWI670281B (zh) 2013-11-06 2019-09-01 西蘭製藥公司 Ｇｉｐ－ｇｌｐ－１雙重促效劑化合物及方法
AU2014345570B2 (en) * 2013-11-06 2019-01-24 Zealand Pharma A/S Glucagon-GLP-1-GIP triple agonist compounds
JOP20200119A1 (ar) * 2015-01-09 2017-06-16 Lilly Co Eli مركبات مساعد مشترك من gip وglp-1
WO2016198624A1 (fr) 2015-06-12 2016-12-15 Sanofi Dérivés d'exendine 4 utilisés en tant qu'agonistes trigonaux des récepteurs du glp-1/glucagon/gip
TWI700291B (zh) * 2015-06-22 2020-08-01 美國禮來大藥廠 升糖素及glp-1共激動劑化合物
TWI622596B (zh) * 2015-10-26 2018-05-01 美國禮來大藥廠 升糖素受體促效劑
WO2017116205A1 (fr) 2015-12-31 2017-07-06 한미약품 주식회사 Conjugué persistant d'un triple activateur activant le récepteur du glucagon, du glp-1 et du gip
EP3217027A1 (fr) 2016-03-08 2017-09-13 HILTI Aktiengesellschaft Élement de revetement large destine a entourer une tige d'ancrage
TWI767095B (zh) * 2017-12-21 2022-06-11 美商美國禮來大藥廠 腸促胰島素(incretin)類似物及其用途
TW202415675A (zh) 2017-12-21 2024-04-16 美商美國禮來大藥廠 腸促胰島素(incretin)類似物及其用途
SG11202100128UA (en) * 2018-07-23 2021-02-25 Lilly Co Eli Gip/glp1 co-agonist compounds
WO2020023388A1 (fr) * 2018-07-23 2020-01-30 Eli Lilly And Company Procédé d'utilisation d'un co-agoniste de gip/glp1 contre le diabète
AR119471A1 (es) * 2019-08-01 2021-12-22 Lilly Co Eli Compuestos agonistas de gipr
TWI795698B (zh) * 2019-12-18 2023-03-11 美商美國禮來大藥廠 腸促胰島素(incretin)類似物及其用途
MX2022009149A (es) * 2020-01-23 2022-12-15 Lilly Co Eli Compuestos coagonistas de gip/glp1.
US20240270821A1 (en) * 2023-01-31 2024-08-15 Eli Lilly And Company Gip/glp1/gcg tri-receptor agonists and uses thereof

Also Published As

Publication number Publication date
US20250059251A1 (en) 2025-02-20
TWI744579B (zh) 2021-11-01
NZ765277A (en) 2024-08-30
CN111491658B (zh) 2024-04-26
CR20200255A (es) 2020-07-12
CN111491658A (zh) 2020-08-04
JP6961838B2 (ja) 2021-11-05
SG11202005606VA (en) 2020-07-29
CL2020001635A1 (es) 2020-10-16
TW202202518A (zh) 2022-01-16
CA3084005C (fr) 2024-01-02
AU2018388962A1 (en) 2020-06-04
BR112020010244A2 (pt) 2020-10-13
CO2020006255A2 (es) 2020-05-29
KR20220133304A (ko) 2022-10-04
KR102622642B1 (ko) 2024-01-10
JP7658877B2 (ja) 2025-04-08
WO2019125938A1 (fr) 2019-06-27
DOP2020000123A (es) 2020-08-31
MX2020006548A (es) 2020-09-14
ECSP20032650A (es) 2020-07-31
US20200331980A1 (en) 2020-10-22
MX2024010201A (es) 2024-08-26
EP3727426A1 (fr) 2020-10-28
JP2021506955A (ja) 2021-02-22
KR20200088419A (ko) 2020-07-22
US11542313B2 (en) 2023-01-03
JP2022033724A (ja) 2022-03-02
US20230203121A1 (en) 2023-06-29
UA129012C2 (uk) 2024-12-25
MY199143A (en) 2023-10-17
TW202415675A (zh) 2024-04-16
PE20210162A1 (es) 2021-01-26
AR113486A1 (es) 2020-05-06
PH12020551025A1 (en) 2021-09-06
EA202091290A1 (ru) 2020-09-10
TWI809515B (zh) 2023-07-21
JP2025093970A (ja) 2025-06-24
IL275468A (en) 2020-08-31
KR102444783B1 (ko) 2022-09-19
CA3084005A1 (fr) 2019-06-27
AU2018388962B2 (en) 2020-11-19
TW201938188A (zh) 2019-10-01
JOP20200137A1 (ar) 2022-10-30

Similar Documents

Publication Publication Date Title
MA51288A (fr) Analogues d'incrétine et leurs utilisations
MA51287A (fr) Analogues d'incrétine et leurs utilisations
MA50618A (fr) Polyrhérapies et leurs utilisations
EP3471727A4 (fr) Inhibiteurs de cxcr4 et leurs utilisations
EP3472129A4 (fr) Inhibiteurs de cxcr4 et leurs utilisations
EP3383916A4 (fr) Anticorps anti-cd73 et leurs utilisations
EP3389702A4 (fr) Anticorps anti-lag-3 et leurs utilisations
MA47789A (fr) Anticorps anti-phf-tau et leurs utilisations
EP3413816A4 (fr) Compositions hydratantes et utilisations associées
EP3426288A4 (fr) Anticorps anti-pacap et leurs utilisations
EP3344275A4 (fr) Macrocycles peptidomimétiques et leurs utilisations
MA46990A (fr) Compositions de glp-1 et leurs utilisations
MA49537A (fr) Anticorps anti-lag3 et leurs utilisations
MA42622A (fr) Agents de liaison à tigit et leurs utilisations
MA46704A (fr) Anticorps anti-pyroglutamate- amyloïde-beta et leurs utilisations
MA41460A (fr) Agents de liaison à la tnfrsf et leurs utilisations
EP3344624A4 (fr) Inhibiteurs de tyk2 et leurs utilisations
EP3294318A4 (fr) Macrocycles peptidomimétiques et leurs utilisations
EP3471726A4 (fr) Inhibiteurs de cxcr4 et leurs utilisations
EP2968443A4 (fr) Analogues d'hepcidine et leurs utilisations
EP3886843A4 (fr) Inhibiteurs de tyk2 et leurs utilisations
EP3283517A4 (fr) Anticorps anti-pacap et leurs utilisations
MA45125A (fr) Anticorps anti-alpha-synucléine et leurs utilisations
MA49886A (fr) Anticorps anti-par2 et leurs utilisations
MA43567A (fr) Anticorps pacap et leurs utilisations